VascularInhibitory Effects of PRG4 on Migration and Proliferation of Human Venous Cells
Introduction
Saphenous vein grafts are commonly used to bypass atherosclerotic arteries of the heart and limbs. Unfortunately, up to 30% of these grafts fail midterm, that is, during the first 18 mo1, 2, 3 because of intimal hyperplasia and adverse remodeling by mechanisms that remain largely unknown.4 This contrasts with late-term failure (>2 y), which results from atherosclerosis that can be treated with drugs such as statins,5 and early failure (<1 mo), which results from thrombosis from technical problems. In contrast to late-term failure, atherosclerotic risk factors, such as plasma cholesterol and diabetes, do not predict midterm vein graft failure.6
We have recently reported that proteoglycan 4 (PRG4, lubricin) is a member of two novel weighted gene co-expression network modules that are associated with midterm human vein graft failure.7 PRG4 was first discovered as an N-terminal fragment that increased proliferative activity of cells of endothelial and hematopoietic lineage.8,9 It has anti-inflammatory and lubricating properties10,11 that protect against both age- and injury-induced osteoarthritis, surgical adhesions, and epithelial dysfunction in a model of cystitis.12, 13, 14, 15, 16, 17 PRG4 inhibits inflammation and fibrosis,10,13,14,18,19 which may play a role in vein graft failure.4,20 However, nothing is known about the potential effects on cell proliferation and migration, which play a central role in intimal hyperplasia. Therefore, we have investigated the effects of recombinant human PRG4 (rhPRG4) on cell migration and proliferation using ex vivo and in vitro human vein models.
Section snippets
Materials
Recombinant rhPRG4 was produced as an endotoxin-free full-length product in CHO-M cells by Lubris BioPharma (Framingham, MA, USA).21
Veins
Two different sets of veins from patients with normal kidney function were obtained for study. In the first, paired human saphenous vein remnants obtained at the time of peripheral vascular bypass and at the time of reoperation for vein graft stenosis were fixed for histology with patient consent under protocols approved by Asahikawa Medical University (Asahikawa,
PRG4 is increased in the media of veins after ex vivo culture
In human vein specimens left over from bypass surgery, PRG4 was seen associated with elastic fibers in the adventitia, endothelial cells of the vasa vasorum, and with remaining luminal endothelial cells (arrows, Fig. 1A). In regard to the latter, about half of the luminal endothelial cells are lost during surgical preparation of the grafts in the operating room (data not presented).29 There was little or no PRG4 immunostaining in the media or intima (Fig. 1A, the medial-adventitial boundary is
Discussion
We observed that rhPRG4 inhibits major aspects of the vascular response to injury—namely, cell migration and proliferation. In the case of migration, PRG4 inhibits SMCs, adventitial cells, and endothelial cells, whereas in the case of proliferation, it only inhibits endothelial cells. The integrated effect of inhibiting these three distinct cell types on intimal hyperplasia in a vein graft is not clear. The inhibitory effect on SMCs, which have been considered the major culprit cell of intimal
Acknowledgment
The authors thank Dr Nam Tran, Dr Niten Singh, Dr Ben Starnes, Dr Elina Quiroga, Dr Mark Meissner, Mike Crandall, and Wendy Hamar (Department of Surgery, University of Washington, Seattle, WA) for help with procurement of vein specimens. The authors also thank Alyssa Morin for help with Western blots.
This work was supported by an unrestricted gift from Lubris Biopharma, Inc (RDK); an American Heart Association Grant-in-Aid (RDK); and a Liaoning Province science and technology research project
References (56)
- et al.
A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia
J Vasc Surg
(2019) - et al.
Vein graft failure
J Vasc Surg
(2015) - et al.
Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and beta-blockers after coronary artery bypass graft surgery
Am Heart J
(2011) - et al.
Factors associated with primary vein graft occlusion in a multicenter trial with mandated ultrasound surveillance
J Vasc Surg
(2014) - et al.
Scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN) are hub genes of coexpression network modules associated with peripheral vein graft patency
J Vasc Surg
(2016) - et al.
Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages
Blood
(2004) - et al.
The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model
Osteoarthritis Cartilage
(2015) - et al.
Recombinant human lubricin for prevention of postoperative intra-abdominal adhesions in a rat model
J Surg Res
(2017) - et al.
Preclinical animal studies of intravesical recombinant human proteoglycan 4 (rhPRG4) as a novel potential therapy for diseases resulting from increased bladder permeability
Urology
(2018) - et al.
Human pericardial proteoglycan 4 (lubricin): implications for postcardiotomy intrathoracic adhesion formation
J Thorac Cardiovasc Surg
(2018)
A single nucleotide polymorphism of cyclin-dependent kinase inhibitor 1B (p27Kip1) associated with human vein graft failure affects growth of human venous adventitial cells but not smooth muscle cells
J Vasc Surg
Smooth muscle cells of human veins show an increased response to injury at valve sites
J Vasc Surg
Surgical marking pen dye inhibits saphenous vein cell proliferation and migration in saphenous vein graft tissue
J Vasc Surg
A single nucleotide polymorphism of cyclin-dependent kinase inhibitor 1B (p27(Kip1)) associated with human vein graft failure affects growth of human venous adventitial cells but not smooth muscle cells
J Vasc Surg
Clinical factors that influence the cellular responses of saphenous veins used for arterial bypass
J Vasc Surg
Porcine coronary artery organ culture: a model for the study of angioplasty injury
Cardiovasc Pathol
A single nucleotide polymorphism in the p27(Kip1) gene is associated with primary patency of lower extremity vein bypass grafts
J Vasc Surg
Proliferative capacity of vein graft smooth muscle cells and fibroblasts in vitro correlates with graft stenosis
J Vasc Surg
Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44
J Biol Chem
Platelet-derived growth factor beta-receptor, transforming growth factor beta type I receptor, and CD44 protein modulate each other's signaling and stability
J Biol Chem
Fibronectin mediates enhanced wear protection of lubricin during shear
Biomacromolecules
In vitro differences between smooth muscle cells derived from varicose veins and normal veins
J Vasc Surg
Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery
J Vasc Surg
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: prevent IV: a randomized controlled trial
J Am Med Assoc
Hemangiopoietin promotes endothelial cell proliferation through PI-3K/Akt pathway
Cell Physiol Biochem
The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid
Arthritis Res Ther
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
J Clin Invest
Proteoglycan 4 expression protects against the development of osteoarthritis
Sci Transl Med
Cited by (0)
- 1
Current address: Department of Surgery, Ohio State University Wexner Medical Center, 452 W 10th Ave, Columbus, OH 43210, USA.